Humoral immune response to thymidylate synthase in colon cancer patients after 5-FU chemotherapy

Yuriy V. Shebzukhov, Ekaterina P. Koroleva, Svetlana V. Khlgatian, Maria A. Lagarkova, Andrey A. Meshcheryakov, Mikhail R. Lichinitser, Julia Karbach, Elke Jager, Dmitry V. Kuprash, Sergei A. Nedospasov

Producción científica: Articlerevisión exhaustiva

11 Citas (Scopus)

Resumen

Thymidylate synthase (TYMS), the critical enzyme for DNA synthesis and a target for chemotherapy, was recently characterized as an oncogene and a potential target for specific immunotherapy. Here we report TYMS-specific antibody response in a fraction of colon cancer patients. Humoral immune response to TYMS is induced by chemotherapy using TYMS inhibitors, such as 5-fluorouracil (5-FU), and may be associated with tumor burden. Therefore, TYMS may serve as a useful serological biomarker for monitoring the course of disease and treatment in cancer patients.

Idioma originalEnglish (US)
Páginas (desde-hasta)88-93
Número de páginas6
PublicaciónImmunology Letters
Volumen100
N.º1
DOI
EstadoPublished - ago 15 2005
Publicado de forma externa

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Huella

Profundice en los temas de investigación de 'Humoral immune response to thymidylate synthase in colon cancer patients after 5-FU chemotherapy'. En conjunto forman una huella única.

Citar esto